Evidence map›Paper›PMID 23321323›Full record

ArticleThe American journal of pathology2013

Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis.

Syed J Kazmi, Stephanie J Byer, Jenell M Eckert, Amy N Turk, Richard P H Huijbregts, Nicole M Brossier, William E Grizzle, Fady M Mikhail, Kevin A Roth, Steven L Carroll

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of pathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Role of nerves in neurofibromatosis type 1-related nervous system tumors.Cellular oncology (Dordrecht, Netherlands) · 2022
    Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Syed J KazmiDepartment of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama 35294-0017, USA.
Stephanie J Byer
Jenell M Eckert
Amy N Turk
Richard P H Huijbregts
Nicole M Brossier
William E Grizzle
Fady M Mikhail
Kevin A Roth
Steven L Carroll
University of Alabama at Birmingham · US

Funding

Alabama Neuroscience Blueprint Core CenterP30NS057098 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ROTH, KEVIN A · 2006 to 2010
$9.5M
Novel Treatment of NF-1 Associated Malignant Peripheral Nerve Sheath TumorsR01CA122804 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CARROLL, STEVEN L. · 2008 to 2012
$1.5M
Role of Neuregulin-1 in Schwann Cell NeoplasiaR01NS048353 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CARROLL, STEVEN L. · 2004 to 2008
$1.3M
Multi-Modal Lysosomotropic Death Therapy for Malignant Peripheral Nerve Sheath TuR01CA134773 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ROTH, KEVIN A · 2009 to 2011
$722k
Regulation of Ras isoforms in malignant peripheral nerve sheath tumorsF30NS063626 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BROSSIER, NICOLE MARIE · 2008 to 2011
$119k
NCI NIH HHS R01 CA122804NCI NIH HHS R01 CA134773NINDS NIH HHS F30 NS063626NINDS NIH HHS P30 NS057098NINDS NIH HHS P30 NS474466NINDS NIH HHS R01 NS048353
6 · The paper itself

Abstract

Patients with neurofibromatosis type 1 (NF1) develop benign plexiform neurofibromas that frequently progress to become malignant peripheral nerve sheath tumors (MPNSTs). A genetically engineered mouse model that accurately models plexiform neurofibroma-MPNST progression in humans would facilitate identification of somatic mutations driving this process. We previously reported that transgenic mice overexpressing the growth factor neuregulin-1 in Schwann cells (P(0)-GGFβ3 mice) develop MPNSTs. To determine whether P(0)-GGFβ3 mice accurately model human neurofibroma-MPNST progression, cohorts of these animals were monitored through death and were necropsied; 94% developed multiple neurofibromas, with 70% carrying smaller numbers of MPNSTs. Nascent MPNSTs were identified within neurofibromas, suggesting that these sarcomas arise from neurofibromas. Although neurofibromin expression was maintained, P(0)-GGFβ3 MPNSTs exhibited Ras hyperactivation, as in human NF1-associated MPNSTs. P(0)-GGFβ3 MPNSTs also exhibited abnormalities in the p16(INK4A)-cyclin D/CDK4-Rb and p19(ARF)-Mdm-p53 pathways, analogous to their human counterparts. Array comparative genomic hybridization (CGH) demonstrated reproducible chromosomal alterations in P(0)-GGFβ3 MPNST cells (including universal chromosome 11 gains) and focal gains and losses affecting 39 neoplasia-associated genes (including Pten, Tpd52, Myc, Gli1, Xiap, and Bbc3/PUMA). Array comparative genomic hybridization also identified recurrent focal copy number variations affecting genes not previously linked to neurofibroma or MPNST pathogenesis. We conclude that P(0)-GGFβ3 mice represent a robust model of neurofibroma-MPNST progression useful for identifying novel genes driving neurofibroma and MPNST pathogenesis.

Indexed as

Disease ProgressionAnimalsBase PairingBiomarkers, TumorCell CycleCell Transformation, NeoplasticChromosomes, MammalianComparative Genomic HybridizationDisease Models, AnimalDNA Copy Number VariationsHumansMiceMice, Inbred C57BLMice, TransgenicNerve Sheath NeoplasmsNeuregulin-1Biomarkers, TumorNeuregulin-1Neurofibromin 1ras Proteins

Identifiers

PMID23321323
PMCPMC3586689
OpenAlexW2153862284

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.